Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the AU2 combination (acalabrutinib, umbralisib, and ublituximab) in relapsed and untreated chronic lymphocytic leukemia and small lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: Jennifer R. Brown, MD, PhD | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-27